You can buy or sell BSTC and other stocks, options, ETFs, and crypto commission-free!
BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren's contracture. Read More The company was founded in 1990 and is headquartered in Lynbrook, NY.
Lynbrook, New York
52 Week High
52 Week Low
Markets InsiderMar 18
BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
LYNBROOK, N.Y., March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced with great sadness that Thomas L. Wegman, President of BioSpecifics, passed away on March 13, 2019. Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of D...
Simply Wall StMar 13
Is BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) 18% ROE Better Than Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important.
Yahoo FinanceMar 5
What's in Store for BioSpecifics (BSTC) This Earnings Season?
Shares of BioSpecifics Technologies Corp. BSTC have increased 77.6% in the past year, against the industry’s decline of 16.1%. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. Moreover, BioSpecifics’ earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missed in one, with the average earnings surprise being 17.04%. Let’s see how things are shaping up prior to the announcement of the upcoming fourth-quarter and full-year 2018 results...
$0.82 per share
Expected Mar 26